Trial Profile
Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- 08 Oct 2021 Results comparing vaccine efficacy of single dose to that of three and two doses in protecting against persistent HPV 16 and 18 infection at 10 years post vaccination, published in the Lancet Oncology.
- 23 Jul 2020 Results of pooled analysis of data from 2 trials (NCT00128661 and NCT00923702), assessing the serological assays to monitor antibody responses to single dose HPV vaccines, published in the Vaccine
- 31 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jul 2021.